T-cell receptor recognizing influenza peptide–MHC complexes derived from GC3111B antigens (TCR-GC3111B)

The T-cell receptor (TCR) recognizing influenza peptide–MHC complexes derived from GC3111B antigens is a specialized immune protein responsible for identifying specific viral fragments presented by the host's immune system. GC3111B refers to a quadrivalent influenza vaccine (developed by GC Biopharma) containing antigens from four different influenza strains, including two influenza A and two influenza B strains. The TCRs specific to these antigens play a critical role in the cellular immune response by mediating the destruction of influenza-infected cells and providing long-term immunological memory. In a therapeutic context, these TCRs are studied to evaluate the immunogenicity of vaccines like GC3111B and to understand how the body develops protective T-cell immunity against seasonal flu. They are also potential candidates for TCR-engineered T-cell therapies in immunocompromised patients or as tools for monitoring vaccine efficacy. The interaction between the TCR and the peptide-MHC complex is highly specific, requiring the correct alignment of the viral peptide within the host's HLA molecule to trigger an effective immune defense.

Other names

GC3111B-specific T-cell receptorInfluenza-specific TCRTCR recognizing GC3111B-derived epitopes

The T-cell receptor (TCR) specifically recognizes influenza-derived peptides presented by Major Histocompatibility Complex (MHC) molecules on the surface of infected or antigen-presenting cells. Upon binding to these peptide-MHC complexes, the TCR triggers intracellular signaling pathways that lead to T-cell activation, proliferation, and the execution of effector functions such as the killing of infected cells and the secretion of pro-inflammatory cytokines to coordinate the antiviral immune response.